Skip to main content
Fig. 2 | Biomarker Research

Fig. 2

From: Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer

Fig. 2

CONSORT diagram of men with metastatic prostate cancer with circulating tumor cells examined in this study. Cohort A: men with mCRPC starting abiraterone acetate/prednisone or enzalutamide (pre-ARSI), Cohort B: men with mCRPC who were progressing on enzalutamide or abiraterone acetate/prednisone (post-ARSI), and Cohort C: men with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) starting androgen deprivation therapy (ADT) or ADT/docetaxel chemotherapy

Back to article page
\